MAO-B inhibitors

MAO-B inhibitors

Inhibitors of the enzyme monoamine oxidase B. MAO-B helps break down dopamine; inhibiting it prolongs the action of dopamine in the brain. Selegiline is an MAO-B inhibitor.
Mentioned in: Parkinson Disease
References in periodicals archive ?
Results show that the tested substances are powerful selective MAO-B inhibitors, yet with the reversible type of inhibition typical of natural substances and plausibly devoid of any significant side effects.
A recent study confirmed the ability of the Klamin[R] extract to cross the blood brain barrier, not only to stimulate through its PEA and MAO-B inhibitor content the brain dopaminergic activity and cascade, enhancing learning ability and attention in mice, but also to reduce, thanks to its AFA-PC and other antioxidants, the level of lipoperoxidation in mice brain (Sedriep et al.
A number of MAO-B inhibitors used in the clinical setting for treating Parkinson's disease have unwanted side effects.
The clinical impact of MAO-B inhibitors on Parkinson's symptoms was small, and almost all patients required the addition of levodopa to the treatment regimen after 3 or 4 years.
MAO-B inhibitors thus help improve the symptomatic motor effects of PD.
Agents such as the dopamine agonists, COMT inhibitors and MAO-B inhibitors can assist in addressing these.
Depression in patients with dementia can be treated with selected tricyclics, MAO-B inhibitors, and selective serotonin reuptake inhibitor medications.
Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.